FDA cardio panel backs approval of Medicines' cangrelor
This article was originally published in Scrip
After a day of what often was intense debate, The Medicines Company (MDCO) managed to walk away with a solid majority of FDA panelists backing the firm's experimental drug cangrelor – something earlier at the meeting of the Cardiovascular and Renal Drugs Advisory Committee (CRDAC) appeared to be a near impossibility to achieve.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.